Delores Mallory, MT(ASCP)SBB, was the recipient of the John Elliott Memorial Award, which is given to an individual who has given outstanding service to the American Association of Blood Banks.

Delores Mallory's career in blood banking began in 1955 when she graduated from Wayne State University with a Bachelor's degree in Medical Technology; in 1964 she received her SBB. From 1965 to 1981, she was Scientific Director of the Community Blood Center, Dayton, Ohio and from 1981 to 1983, Technical Director of the Irwin Memorial Blood Bank in San Francisco. She is presently Director of the American Red Cross National Reference Laboratory for Blood Group Serology. This includes coordinating the 64 reference laboratory programs located throughout the country, directing national headquarters' Reference Laboratory, and the Rare Donor Registry and Special Services Laboratories.

Delores has presented numerous lectures and papers and has served on too many committees to mention here. She also served on the Board of Directors of the Ohio Association of Blood Banks, who awarded her a lifetime membership in 1981, and on the AABB Board of Directors. She received the AABB Ivor Dunsford Memorial Award in 1976.

In 1984, Delores Mallory redesigned the Red Cross newsletter Red Cell Free Press and it became Immuno- hematology, Journal of Blood Group Serology and Education. Since then, as Editor-in-Chief, she has guided its progress to the position it holds today, an internationally known and respected journal dedicated to blood bank immunohematology and education.

In addition to directing the growth of and writing "Letters from the Editor" for Immuno- hematology, Delores was co-author of "Stimulation of antibody following Chromium survival studies," Immuno- hematology 1987;3(1):6-8.

I would like to take this opportunity to express my thanks to Delores for encouraging me to become a part of this excellent journal. It is so rewarding to work with such fine professionals as the four who received awards and recognition at the 1989 AABB convention.

Mary McGinniss
Managing Editor

To the Editor:

It is true, as Hardman, Beck and Lamley contend in their report,1 that IgG-coated red blood cells treated with ZZAP may be expected to give mostly reliable results when tested with commercial Rh-typing reagents. In fact, specific reactivity is apt to be improved by the treatment, since the cells have been modified with papain. There is a potential problem, however, of which your readers should be made aware. It is that the test procedure is not covered by the directions recommended in the manufacturer's package insert. The Rh-typing reagent is almost certainly not guaranteed to be specific when used to test an enzyme-treated cell suspension. It probably will be on most occasions, but there is always a possibility of an occasional false-positive test result due to an unsuspected contaminating specificity in the reagent. Accordingly, test results should be interpreted cautiously when adopting this procedure.

John Case, FIMLS
Director of Regulatory Affairs
Gamma Biologicals, Inc.


From the Editor

The editors of Immunohematology are grateful to the Baxter Fenwal Division of Baxter International Inc. for its generous contribution in support of the publication of this issue. Baxter Fenwal is a leader in the development of products that allow for the modification of the patient’s immune response. Areas of particular interest are adoptive immunotherapy (LAK, TIL), bone marrow therapy, and plasma therapy (LDL). Baxter, headquartered in Deerfield, Illinois, U.S.A., is the leading worldwide manufacturer and marketer of health care products, systems, and services. It offers 120,000 products to health care providers in more than 100 countries.

The editors would like to thank Baxter for its continuing support and encourage others to make donations that will subsidize the publication of this journal. Inquiries should be directed to Delores Mallory, Editor-in-Chief, Immunohematology, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855, U.S.A. Telephone (301) 738-0505.

Delores Mallory
Editor-in-Chief